Generic Spritam Availability

Last updated on Jun 11, 2025.

Spritam is a brand name of levetiracetam, approved by the FDA in the following formulation(s):

SPRITAM (levetiracetam - tablet, for suspension;oral)

• Manufacturer: APRECIA PHARMS
  Approval date: July 31, 2015
  Strength(s): 1GM (discontinued) ^[RLD], 250MG ^[RLD], 500MG ^[RLD], 750MG (discontinued) ^[RLD]

Is there a generic version of Spritam available?

An Authorized Generic version of Spritam has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.

List of authorized generic versions:

• levetiracetam ORAL TABLET, FOR SUSPENSION 250 mg
  Prasco Laboratories
  NDC Code: 669930100
  

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Spritam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Rapid disperse dosage form
  Patent 11,160,786
  Issued: November 2, 2021
  Inventor(s): Jacob Jules & Coyle Norman & West Thomas G. & Monkhouse Donald C. & Surprenant Henry L. & Jain Nemichand B.
  Assignee(s): APRECIA PHARMACEUTICALS LLC
  

  A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of water soluble drug in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to the drug.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Drug product
• Rapid disperse dosage form containing levetiracetam
  Patent 9,339,489
  Issued: May 17, 2016
  Inventor(s): Jacob Jules & Coyle Norman & West Thomas G & Monkhouse Donald C. & Surprenant Henry L. & Jain Nemichand B.
  Assignee(s): Aprecia Pharmaceuticals Company
  

  A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 10 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: METHOD OF ADMINISTERING LEVETIRACETAM
    ✓ 
    Drug product
• Rapid disperse dosage form containing levetiracetam
  Patent 9,669,009
  Issued: June 6, 2017
  Inventor(s): Jacob Jules & Coyle Norman & West Thomas G. & Monkhouse Donald C. & Surprenant Henry L. & Jain Nemichand B.
  Assignee(s): Aprecia Pharmaceuticals Company
  

  A high dose rapidly dispersing three-dimensionally printed dosage form comprising a high dose of levetiracetam in a porous matrix that disperses in water within a period of less than about 15 seconds is disclosed. Also disclosed are methods of preparing the dosage form and of treating a condition, disease or disorder that is therapeutically responsive to levetiracetam.

  Patent expiration dates:

  • March 14, 2034
    
    ✓ 
    Patent use: METHOD OF ADMINISTERING LEVETIRACETAM
  • March 14, 2034
    
    ✓ 
    Patent use: METHOD OF ADMINISTERING LEVETIRACETAM UNDER FASTED CONDITIONS
  • March 14, 2034
    
    ✓ 
    Patent use: METHOD OF ADMINISTERING LEVETIRACETAM UNDER FED CONDITIONS

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer